Cerus Co. (NASDAQ:CERS – Get Rating) shares hit a new 52-week low during trading on Tuesday . The company traded as low as $3.42 and last traded at $3.42, with a volume of 30076 shares. The stock had previously closed at $3.47.
Cerus Trading Down 1.7 %
The stock has a market cap of $603.88 million, a P/E ratio of -14.46 and a beta of 1.14. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.08 and a quick ratio of 1.73. The business's 50 day simple moving average is $4.68 and its 200 day simple moving average is $4.98.
Get
Cerus alerts:
Insider Activity
In other news, insider Richard J. Benjamin sold 10,000 shares of Cerus stock in a transaction that occurred on Tuesday, August 9th. The shares were sold at an average price of $5.12, for a total value of $51,200.00. Following the completion of the transaction, the insider now owns 172,665 shares in the company, valued at $884,044.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 7.33% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
A number of institutional investors have recently modified their holdings of the company. Legal & General Group Plc raised its stake in shares of Cerus by 9.9% in the second quarter. Legal & General Group Plc now owns 328,358 shares of the biotechnology company's stock valued at $1,737,000 after acquiring an additional 29,597 shares during the last quarter. ExodusPoint Capital Management LP raised its position in Cerus by 3.8% in the 2nd quarter. ExodusPoint Capital Management LP now owns 233,339 shares of the biotechnology company's stock worth $1,234,000 after purchasing an additional 8,516 shares during the last quarter. Walleye Capital LLC bought a new position in Cerus in the 2nd quarter worth approximately $154,000. Goldman Sachs Group Inc. raised its position in Cerus by 102.4% in the 2nd quarter. Goldman Sachs Group Inc. now owns 863,845 shares of the biotechnology company's stock worth $4,570,000 after purchasing an additional 437,101 shares during the last quarter. Finally, Tamarack Advisers LP raised its position in Cerus by 21.2% in the 2nd quarter. Tamarack Advisers LP now owns 2,000,000 shares of the biotechnology company's stock worth $10,580,000 after purchasing an additional 350,000 shares during the last quarter. Institutional investors own 84.72% of the company's stock.
About Cerus
(Get Rating)
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Further Reading
- Get a free copy of the StockNews.com research report on Cerus (CERS)
- Build A Better Tech Portfolio With Jabil Inc.
- Is There Value In These Growth Stocks?
- Autodesk Is A Mature Company Still Acting Like A Growth Stock
- MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
- Is the Market Overreacting with Shopify Stock?
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.
